User: Guest  Login
Title:

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Document type:
Article; Randomized Controlled Trial; Journal Article
Author(s):
Mayne, Kaitlin J; Staplin, Natalie; Keane, David F; Wanner, Christoph; Brenner, Susanne; Cejka, Vladimir; Stegbauer, Johannes; Judge, Parminder K; Preiss, David; Emberson, Jonathan; Trinca, Daniele; Dayanandan, Rejive; Lee, Ryonfa; Nolan, John; Omata, Akiko; Green, Jennifer B; Cherney, David Z I; Hooi, Lai Seong; Pontremoli, Roberto; Tuttle, Katherine R; Lees, Jennifer S; Mark, Patrick B; Davies, Simon J; Hauske, Sibylle J; Steubl, Dominik; Brückmann, Martina; Landray, Martin J; Baigent, Colin;...     »
Abstract:
SIGNIFICANCE STATEMENT: SGLT2 inhibitors reduce risk of kidney progression, AKI, and cardiovascular disease, but the mechanisms of benefit are incompletely understood. Bioimpedance spectroscopy can estimate body water and fat mass. One quarter of the EMPA-KIDNEY bioimpedance substudy CKD population had clinically significant levels of bioimpedance-derived "Fluid Overload" at recruitment. Empagliflozin induced a prompt and sustained reduction in "Fluid Overload," irrespective of sex, diabetes, an...     »
Journal title abbreviation:
J Am Soc Nephrol
Year:
2024
Journal volume:
35
Journal issue:
2
Pages contribution:
202-215
Fulltext / DOI:
doi:10.1681/ASN.0000000000000271
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/38082486
Print-ISSN:
1046-6673
TUM Institution:
1121; Professur für Nephrologie (Prof. Heemann)
 BibTeX